insights_auto
Kwa nini LYEL imeongezeka kwa 2.50%?
Fahamu zaidichevron_right
LYEL:NASDAQ
Lyell Immunopharma Inc
US$Â 8.19
arrow_upward
+2.50%(+0.20) Siku 1
US$Â 8.19
0.00% (0.00)
bedtimeBaada ya saa
Imefungwa: 15 Okt, 16:00:01 GMT -4 · USD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya LYEL...
Fungua
US$Â 8.00
Juu
US$Â 8.44
Chini
US$Â 7.76
Mtaji wa soko
200.70M
Wastani wa kiasi cha mauzo
elfu 149.51
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$Â 45.00
Chini kwa wiki 52
US$Â 7.32
EPS
-US$Â 12.01
Beta
-0.03
Hisa za wawekezaji
24.50M
Idadi ya wafanyakazi
161
Fungua
US$Â 8.00
Juu
US$Â 8.44
Chini
US$Â 7.76
Mtaji wa soko
200.70M
Wastani wa kiasi cha mauzo
elfu 149.51
Kiasi cha mauzo ya hisa
0.00
Juu kwa wiki 52
US$Â 45.00
Chini kwa wiki 52
US$Â 7.32
EPS
-US$Â 12.01
Beta
-0.03
Hisa za wawekezaji
24.50M
Idadi ya wafanyakazi
161
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Stock Titan
·
siku 2 zilizopita
An automatic tax-cover sale leaves Lyell Immunopharma (LYEL) medical chief holding 19,857 shares.
Wasifu
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
Kuhusu Lyell Immunopharma Inc
Afisa Mkuu Mtendaji (CEO)-
Wafanyakazi161
Lilianzishwa2018
Makao makuuSouth San Francisco, California, Marekani
Sekta-
Tovutilyell.com